Detecting Nephrotoxicity Using Early Markers and Imaging Tools 2011

KIDNEY MARKERS: FROM BENCH TO BEDSIDE

Pre-Clinical Biomarkers of Nephrotoxicity: Applications in Drug Discovery and Development
Eric Blomme, D.V.M., Ph.D., DACVP, Senior Project Leader, Abbott Laboratories
Talk Title to be Announced
Stephen Furlong, Ph.D., Safety Science Lead, U.S., Patient Safety, AstraZeneca (tentative)
Rapid Point-of-Care GFR: Technique, Diagnostic and Therapeutic Advantages
Bruce A. Molitoris, M.D., Director, Division of Nephrology and Professor of Medicine, Indiana University

UNDERSTANDING MECHANISMS
OF NEPHROTOXICITY

Cisplatin Nephrotoxicity and Renal Protective Strategies
Zheng Dong, Ph.D., Professor, Department of Cellular Biology and Anatomy, Medical College of Georgia

MITOCHONDRIAL INVOLVEMENT IN
CARDIAC, RENAL AND LIVER TOXICITY

Talk Title to be Announced
Yvonne Will, Ph.D., Associate Research Fellow, Compound Safety Prediction, Pfizer Global R&D